Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study

Hao, Mingzhi; Lin, Huilong; Chen, Qiang; Ye, Yunbin; Chen, Qizhong; Chen, Ming-Shui

doi:10.5732/cjc.009.10410

Cited by 50 publications

(43 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 19 included papers comprised 11 randomized controlled studies [20–22,26,28,29,32,34,35,37,38], 1 studies without describing the randomization method [25] and 7 retrospective studies with a matched-pair control group [23,24,27,30,31,33,36]. It contained eleven (57.89%) with all low risk of bias, one (5.26%) with unclear risk and seven (36.84%) with high risk of bias in random sequence generation, allocation concealment, blinding of participants and personnel and blinding of outcome assessment items, as was shown in S1 Fig.…”

Section: Resultsmentioning

confidence: 99%

“…However, TACE-predominant minimally-invasive Treatment might damage the liver function, reduce the resistance and immunity, and lead to tumor recurrence and residual. So, the combination of TACE-predominant minimally-invasive Treatment and immunotherapy might become an effective treatment [41]. From 18 meta-analysis or reviews in this field, 3 out of 18 performed a meta-analysis on HCC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients

et al. 2016

View full text Add to dashboard Cite

PurposeCellular immunotherapy has appeared to be a promising modality for the treatment of malignant tumor. The objective of this study was to evaluate the efficacy of cellular immunotherapy combined with minimally invasive therapy.MethodsWe searched PubMed, Web of Science and The Cochrane Library through March 2016 for relevant studies. Short-term efficacy (the disease control rate, the control rate of quality life and the AFP descent rate) and long-term efficacy (overall survival (OS) and progression-free survival (PFS) rate) were compared as the major outcome measures. The meta-analysis was performed using Review Manager 5.3.ResultsA total of 1174 references in 3 databases were found of which 19 individual studies with 1774 HCC patients enrolled in this meta-analysis. Meta-analysis results showed that cellular immunotherapy combined with minimally-invasive treatment significantly improved the measures of short-term response (the disease control rate (OR = 5.91, P = 0.007), the control rate of quality lift (OR = 3.38, P = 0.003) and the AFP descent rate (OR = 4.48, P = 0.02)). Also higher 6-month PFS (OR = 2.78, P = 0.05), ≥12-month PFS (OR = 3.56, P<0.00001) rate and 6-month OS (OR = 2.81, P = 0.0009), 12-month OS (OR = 3.05, P<0.00001) and 24-month OS (OR = 3.52, P<0.0001) rate were observed in patients undergoing cellular immunotherapy.ConclusionsThis meta-analysis suggested that cellular immunotherapy is a feasible adjuvant treatment that could be beneficial for the improvement of the clinical outcomes for hepatocellular carcinoma (HCC) patients after minimally invasive treatment, including short-term response and long-term survival.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients

et al. 2016

View full text Add to dashboard Cite

show abstract

“…After considering the inclusion and exclusion criteria, eight randomized trials,13,14,18,23–27 six prospective studies,15,28–33 and three retrospective studies16,17,32 were eligible for this review (Figure 2). The eligible studies analyzed a total of 1,979 patients with HCC, 1,029 of whom underwent adjuvant immunotherapy with CIK cells.…”

Section: Resultsmentioning

confidence: 99%

Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis

Yang

Chi

et al. 2017

DDDT

View full text Add to dashboard Cite

This study was designed to evaluate the efficacy and safety of cytokine-induced killer (CIK) cell-based immunotherapy as an adjuvant therapy for hepatocellular carcinoma (HCC). Published studies were identified by searching Medline, Cochrane, EMBASE, and Google Scholar databases with the keywords: cytokine-induced killer cell, hepatocellular carcinoma, and immunotherapy. The outcomes of interest were overall survival, progression-free survival, and disease-free survival. Eight randomized controlled trials (RCTs), six prospective studies, and three retrospective studies were included. The overall analysis revealed that patients in the CIK cell-treatment group had a higher survival rate (pooled hazard ratio (HR) =0.594, 95% confidence interval [CI] =0.501–0.703, P<0.001). Patients treated with CIK cells in non-RCTs had a higher progression-free survival rate (pooled HR =0.613, 95% CI =0.510–0.738, P<0.001). However, CIK cell-treated patients in RCTs had progression-free survival rates similar to those of the control group (pooled HR =0.700, 95% CI =0.452–1.084, P=0.110). The comparison between pooled results of RCTs and non-RCTs regarding the progression-free survival rate did not reach statistical significance. Patients in the CIK cell-treatment group had lower rates of relapse in RCTs (pooled HR =0.635, 95% CI =0.514–0.784, P<0.001). Similar results were found when non-RCT and RCTs were pooled (pooled HR =0.623, 95% CI =0.516–0.752, P<0.001). Adjuvant CIK cell-based immunotherapy is a promising therapeutic approach that can improve overall survival and reduce recurrence in patients with HCC.

show abstract

“…Schmidt-Wolf et al (1991) reported the anticancer potential of CIK cells and confirmed that CIK cells suppress the tumor burden and prolong survival of the murine severe combined immune deficiency (SCID)/human lymphoma models for the first time. Clinical studies have shown high efficiency, low toxicity (Liu et al, 2012), and prolonged overall survival (OS) and disease-free survival (DFS) after CIK treatment (Hao et al, 2010;Pan et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients

Lan

Chen

Wang

et al. 2015

J. Zhejiang Univ. Sci. B

View full text Add to dashboard Cite

Abstract:Objective: Professional antigen-presenting dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic resistance. To evaluate whether DC-CIK cell-based therapy improves the clinical efficacy of chemotherapy, we reviewed the literature on DC-CIK cells and meta-analyzed randomized controlled trials (RCTs). Methods: We searched several databases and selected studies using predefined criteria. RCTs that applied chemotherapy with and without DC-CIK cells separately in two groups were included. Odds ratio (OR) and mean difference (MD) were reported to measure the pooled effect. Results: Twelve reported RCTs (826 patients), which were all performed on Chinese patients, were included. Combination therapy exhibited better data than chemotherapy: 1-year overall survival (OS) (OR=0.

show abstract

Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study

Cited by 50 publications

References 0 publications

Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients

Is Adjuvant Cellular Immunotherapy Essential after TACE-Predominant Minimally-Invasive Treatment for Hepatocellular Carcinoma? A Systematic Meta-Analysis of Studies Including 1774 Patients

Efficacy of cytokine-induced killer cell infusion as an adjuvant immunotherapy for hepatocellular carcinoma: a systematic review and meta-analysis

Immunotherapy of DC-CIK cells enhances the efficacy of chemotherapy for solid cancer: a meta-analysis of randomized controlled trials in Chinese patients

Contact Info

Product

Resources

About